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There is evidence that the potential for high concentration oxygen therapy to increase PaCO2 is not limited to
stable and acute exacerbations of COPD, but also to other acute respiratory disorders with abnormal gas exchange
such as asthma and pneumonia, and chronic respiratory conditions with hypercapnia such as obesity
hypoventilation syndrome. This evidence forms the basis of consensus guidelines which recommend that oxygen
therapy is titrated in COPD and other respiratory conditions, to ensure the maximal benefits of oxygen therapy are
achieved while reducing the potential for harm due to hyperoxia.The risks associated with high concentration oxygen
therapy in acute exacerbations of chronic obstructive
pulmonary disease (COPD) were reported over 50 years
ago [1]. Since then it has been demonstrated that high
concentration oxygen therapy can cause an increase in
PaCO2 in both stable COPD and exacerbations of
COPD, and that in some patients the effect can be both
rapid and marked with an increase in PaCO2 of >20
mmHg within 60 minutes [2]. The clinical significance
of this effect is evident from the recent randomised con-
trolled trial (RCT) which demonstrated that in acute
exacerbations of COPD, high concentration oxygen ther-
apy in the pre-hospital setting significantly increases
mortality compared with a titrated regimen to achieve
arterial oxygen saturations between 88% and 92% [3]. In
patients with confirmed COPD who received oxygen
therapy treatments as per protocol, the PaCO2 was 34
mmHg higher in the high concentration oxygen therapy
group (Table 1).
The main mechanisms responsible for the increase in
PaCO2 with high concentration oxygen therapy are a re-
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in any medium, provided the original work is pperfusion mismatch due to release of hypoxic pulmonary
vasoconstriction [2,4-7]. Ventilation-perfusion mismatch
is also a predominant gas exchange abnormality in other
acute respiratory disorders such as asthma and pneumo-
nia, with the degree of mismatch worsening with the ad-
ministration of oxygen [8-14]. As a result it would be
expected that high concentration oxygen therapy would
cause an increase in PaCO2 in severe asthma and pneu-
monia, similar to its administration in acute exacerba-
tions of COPD.
Recently a series of RCTs has demonstrated that high
concentration oxygen treatment results in a significant
increase in PaCO2 or transcutaneous carbon dioxide
tension (PtCO2) in patients presenting with severe exac-
erbations of asthma [15-17]. The clinical significance of
this physiological effect is suggested by the observation
that 10% of patients randomised to high concentration
oxygen therapy had an increase in PtCO2 of ≥10 mmHg
and a PtCO2 ≥45 mmHg after 60 minutes of treatment,
whereas no patients receiving titrated oxygen therapy to
maintain the arterial oxygen saturations between 93 and
95% had this response (Figure 1) [15]. In a similar RCT,
high concentration oxygen therapy was also shown to
increase the PtCO2 in patients presenting with
community-acquired pneumonia when compared with
the titrated oxygen regimen which avoided both hypoxia
and hyperoxia [18]. The three- and six-fold relative risks
of an increase in PtCO2 of at least 4 mmHg and at leastn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 High concentration versus titrated oxygen







Mortality 9% 2% 0.22
(0.5 to 0.91)
0.04


















† Treatment per protocol analysis.
Reproduced with modification from reference [3].
Table 2 The proportion of patients with community-
acquired pneumonia with a rise in PtCO2 from baseline
after 60 minutes of high concentration or titrated oxygen
therapy
High concentration Titrated Relative risk P value
n (%) n (%) (95% CI)
Change in PtCO2
≥4 mmHg
36 (50%) 11 (14.7%) 3.4 (1.9 to 6.2) <0.001
Change in PtCO2
≥8 mmHg
11 (15.3%) 2 (2.7%) 5.7 (1.3 to 25.0) 0.007
Reproduced with modification from reference [18].
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tially be of both physiological and clinical significance
(Table 2).
Chronic respiratory failure may also occur in other
chronic respiratory disorders such as obesity hypoven-
tilation syndrome [19], so it might be expected that high
concentration oxygen therapy could cause CO2 retention
in this condition, similar to stable COPD. This physio-
logical effect has recently been demonstrated in a
randomised placebo-controlled trial of 100% oxygen and
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Figure 1 The transcutaneous partial pressure of carbon
dioxide (PtCO2) levels at baseline and after 60 min of high
concentration (open circles) or titrated (filled circles)
oxygen in patients presenting to the Emergency
Department with a severe exacerbation of asthma.
Reproduced from reference [15].syndrome and baseline hypercapnia (Figure 2) [20]. The
main mechanism responsible for the worsening hypercap-
nia when breathing 100% oxygen was a reduction in mi-
nute ventilation, leading to alveolar hypoventilation. The
clinical significance of this physiological effect was sug-
gested by the requirement to terminate the study in one in
eight of the patients studied, due to an increase in PtCO2
≥10 mmHg within 20 minutes of receiving 100% oxygen
therapy.
Thus there is evidence that the potential for high con-
centration oxygen therapy to increase PaCO2 is not lim-
ited to stable and acute exacerbations of COPD, but also
to other acute respiratory disorders with abnormal gas
exchange such as asthma and pneumonia, and chronic
respiratory conditions with hypercapnia such as obesity
hypoventilation syndrome. This evidence forms the basis
of consensus guidelines [21] which recommend that oxy-
gen therapy is titrated in COPD and other respiratory
conditions, to ensure the maximal benefits of oxygen
therapy are achieved while reducing the potential for




















Figure 2 The change in PtCO2 (mmHg) from baseline following
breathing 100% oxygen or room air in subjects with obesity
hypoventilation syndrome. The vertical lines are the mean (central
horizontal line) ±1 SD for 20 min PtCO2 minus baseline. Reproduced
from reference [20].
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